BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang W, Zhang B, Chen XP. Adjuvant treatment strategy after curative resection for hepatocellular carcinoma. Front Med 2021;15:155-69. [PMID: 33754281 DOI: 10.1007/s11684-021-0848-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Luo S, Hu H. Huaier granule prolongs overall survival after curative resection of hepatocarcinoma carcinoma: A propensity score analysis. Journal of Ethnopharmacology 2023;301:115774. [DOI: 10.1016/j.jep.2022.115774] [Reference Citation Analysis]
2 Xiao T, Bao J, Tian J, Lin R, Zhang Z, Zhu Y, He Y, Gao D, Sun R, Zhang F, Cheng Y, Shaletanati J, Zhou H, Xie C, Yang C. Flavokawain A suppresses the vasculogenic mimicry of HCC by inhibiting CXCL12 mediated EMT. Phytomedicine 2023. [DOI: 10.1016/j.phymed.2023.154687] [Reference Citation Analysis]
3 Mao Q, Zhou MT, Zhao ZP, Liu N, Yang L, Zhang XM. Role of radiomics in the diagnosis and treatment of gastrointestinal cancer. World J Gastroenterol 2022; 28(42): 6002-6016 [DOI: 10.3748/wjg.v28.i42.6002] [Reference Citation Analysis]
4 Wang L, Wu M, Zhu C, Li R, Bao S, Yang S, Dong J. Ensemble learning based on efficient features combination can predict the outcome of recurrence-free survival in patients with hepatocellular carcinoma within three years after surgery. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1019009] [Reference Citation Analysis]
5 Zheng S, Pan B. Multilevel data integration and molecular docking approach to systematically elucidate the underlying pharmacological mechanisms of Er-Zhi-Wan against hepatocellular carcinoma. Aging 2022. [DOI: 10.18632/aging.204369] [Reference Citation Analysis]
6 Korsch M, Margetts A, Wahlestedt C, Lohse I. Non-Coding RNAs in Hepatocellular Carcinoma. Livers 2022;2:185-213. [DOI: 10.3390/livers2030017] [Reference Citation Analysis]
7 Marzi L, Mega A, Gitto S, Pelizzaro F, Seeber A, Spizzo G. Impact and Novel Perspective of Immune Checkpoint Inhibitors in Patients with Early and Intermediate Stage HCC. Cancers 2022;14:3332. [DOI: 10.3390/cancers14143332] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Yao LQ, Chen ZL, Feng ZH, Diao YK, Li C, Sun HY, Zhong JH, Chen TH, Gu WM, Zhou YH, Zhang WG, Wang H, Zeng YY, Wu H, Wang MD, Xu XF, Pawlik TM, Lau WY, Shen F, Yang T. Clinical Features of Recurrence After Hepatic Resection for Early-Stage Hepatocellular Carcinoma and Long-Term Survival Outcomes of Patients with Recurrence: A Multi-institutional Analysis. Ann Surg Oncol 2022. [PMID: 35192156 DOI: 10.1245/s10434-022-11454-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Ke Q, Wang L, Wu W, Huang X, Li L, Liu J, Guo W. Meta-Analysis of Postoperative Adjuvant Hepatic Artery Infusion Chemotherapy Versus Surgical Resection Alone for Hepatocellular Carcinoma. Front Oncol 2021;11:720079. [PMID: 35004268 DOI: 10.3389/fonc.2021.720079] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Zhang H, Zhao J, Yang W, Li Z, Gong L, Li Y. Liver Cancer: Interdisciplinary Approach. Interdisciplinary Cancer Research 2022. [DOI: 10.1007/16833_2022_96] [Reference Citation Analysis]
11 Ao H, Xin Z, Jian Z. Liquid biopsy to identify biomarkers for immunotherapy in hepatocellular carcinoma. Biomark Res 2021;9:91. [PMID: 34930486 DOI: 10.1186/s40364-021-00348-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Harputluoglu M, Carr BI. Hepatitis B Before and After Hepatocellular Carcinoma. J Gastrointest Cancer 2021. [PMID: 34762265 DOI: 10.1007/s12029-021-00745-4] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]